Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 2011-11, Vol.25 (11), p.699-702 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 702 |
|---|---|
| container_issue | 11 |
| container_start_page | 699 |
| container_title | Journal of human hypertension |
| container_volume | 25 |
| creator | Sandoo, A Panoulas, V F Toms, T E Smith, J P Stavropoulos-Kalinoglou, A Metsios, G S Gasparyan, A Y Carroll, D Veldhuijzen van Zanten, J J C S Kitas, G D |
| description | |
| doi_str_mv | 10.1038/jhh.2011.36 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_898509294</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>898509294</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-1a39fbaf727b22e6e5477b8dd70cbda706245d4bc3658305adeaccfbbcf409f53</originalsourceid><addsrcrecordid>eNptkd2K1DAYhoMo7rh65LkERDzQjmmaNO3hsrgqLHqyHoc0-brN0CY1P8rcizfhjXhNZpzRBRECIbxP3u_nRehpTbY1abo3u2naUlLX26a9hzY1E23FORX30Yb0nFQ9ZeQMPYpxR8hB7B6iM1pzyruu3aDvFy7Z6ubj1c8fOE0Q1LrHi9rjGZTByeNh9t7gNUCMOQAOYLJO1rtY6ODz7YTtsgb_FQwGZ3yxmG1eKgNreYJLeLG6yCrqPKuAx-x-f8fW4VUlW4iIv9k04TBBXlTy1mAVirdNNj5GD0Y1R3hyus_R56u3N5fvq-tP7z5cXlxXmlGSqlo1_TioUVAxUAotcCbE0BkjiB6MEqSljBs26KblXUO4MqC0HodBj4z0I2_O0cujb5nkS4aY5GKjhnlWDnyOsus7Tnras0I-_4fc-RxcaU7SlpVCDREHv1dHqoweY4BRrsEuKuxlTeQhM1kyk4fMZNMW-tnJMw8LmL_sn5AK8OIElDWqeQzKaRvvOMZFX07hXh-5WCR3C-Guuf_V_QXJvrNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640623075</pqid></control><display><type>article</type><title>Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Sandoo, A ; Panoulas, V F ; Toms, T E ; Smith, J P ; Stavropoulos-Kalinoglou, A ; Metsios, G S ; Gasparyan, A Y ; Carroll, D ; Veldhuijzen van Zanten, J J C S ; Kitas, G D</creator><creatorcontrib>Sandoo, A ; Panoulas, V F ; Toms, T E ; Smith, J P ; Stavropoulos-Kalinoglou, A ; Metsios, G S ; Gasparyan, A Y ; Carroll, D ; Veldhuijzen van Zanten, J J C S ; Kitas, G D</creatorcontrib><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/jhh.2011.36</identifier><identifier>PMID: 21525886</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/443/1338/243 ; 692/420 ; 692/699/249/1313/498 ; 692/700/565/251 ; Adalimumab ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arterial hypertension. Arterial hypotension ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Arthritis, Rheumatoid - physiopathology ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood pressure ; Blood Pressure - drug effects ; Cardiology. Vascular system ; Clinical manifestations. Epidemiology. Investigative techniques. Etiology ; Endothelium ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - immunology ; Endothelium, Vascular - physiopathology ; England ; Epidemiology ; Etanercept ; Health Administration ; Humans ; Immunoglobulin G - therapeutic use ; Inflammation Mediators - blood ; Infliximab ; Longitudinal Studies ; Medical sciences ; Medicine ; Medicine & Public Health ; Microvasculature ; Microvessels - drug effects ; Microvessels - immunology ; Microvessels - physiopathology ; Public Health ; Receptors, Tumor Necrosis Factor - therapeutic use ; research-letter ; Rheumatoid arthritis ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - blood ; Tumor necrosis factor-α</subject><ispartof>Journal of human hypertension, 2011-11, Vol.25 (11), p.699-702</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>2015 INIST-CNRS</rights><rights>Macmillan Publishers Limited 2011.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-1a39fbaf727b22e6e5477b8dd70cbda706245d4bc3658305adeaccfbbcf409f53</citedby><cites>FETCH-LOGICAL-c420t-1a39fbaf727b22e6e5477b8dd70cbda706245d4bc3658305adeaccfbbcf409f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/jhh.2011.36$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/jhh.2011.36$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24579579$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21525886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sandoo, A</creatorcontrib><creatorcontrib>Panoulas, V F</creatorcontrib><creatorcontrib>Toms, T E</creatorcontrib><creatorcontrib>Smith, J P</creatorcontrib><creatorcontrib>Stavropoulos-Kalinoglou, A</creatorcontrib><creatorcontrib>Metsios, G S</creatorcontrib><creatorcontrib>Gasparyan, A Y</creatorcontrib><creatorcontrib>Carroll, D</creatorcontrib><creatorcontrib>Veldhuijzen van Zanten, J J C S</creatorcontrib><creatorcontrib>Kitas, G D</creatorcontrib><title>Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><addtitle>J Hum Hypertens</addtitle><subject>631/443/1338/243</subject><subject>692/420</subject><subject>692/699/249/1313/498</subject><subject>692/700/565/251</subject><subject>Adalimumab</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiology. Vascular system</subject><subject>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</subject><subject>Endothelium</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - immunology</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>England</subject><subject>Epidemiology</subject><subject>Etanercept</subject><subject>Health Administration</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Inflammation Mediators - blood</subject><subject>Infliximab</subject><subject>Longitudinal Studies</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microvasculature</subject><subject>Microvessels - drug effects</subject><subject>Microvessels - immunology</subject><subject>Microvessels - physiopathology</subject><subject>Public Health</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>research-letter</subject><subject>Rheumatoid arthritis</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - blood</subject><subject>Tumor necrosis factor-α</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkd2K1DAYhoMo7rh65LkERDzQjmmaNO3hsrgqLHqyHoc0-brN0CY1P8rcizfhjXhNZpzRBRECIbxP3u_nRehpTbY1abo3u2naUlLX26a9hzY1E23FORX30Yb0nFQ9ZeQMPYpxR8hB7B6iM1pzyruu3aDvFy7Z6ubj1c8fOE0Q1LrHi9rjGZTByeNh9t7gNUCMOQAOYLJO1rtY6ODz7YTtsgb_FQwGZ3yxmG1eKgNreYJLeLG6yCrqPKuAx-x-f8fW4VUlW4iIv9k04TBBXlTy1mAVirdNNj5GD0Y1R3hyus_R56u3N5fvq-tP7z5cXlxXmlGSqlo1_TioUVAxUAotcCbE0BkjiB6MEqSljBs26KblXUO4MqC0HodBj4z0I2_O0cujb5nkS4aY5GKjhnlWDnyOsus7Tnras0I-_4fc-RxcaU7SlpVCDREHv1dHqoweY4BRrsEuKuxlTeQhM1kyk4fMZNMW-tnJMw8LmL_sn5AK8OIElDWqeQzKaRvvOMZFX07hXh-5WCR3C-Guuf_V_QXJvrNQ</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Sandoo, A</creator><creator>Panoulas, V F</creator><creator>Toms, T E</creator><creator>Smith, J P</creator><creator>Stavropoulos-Kalinoglou, A</creator><creator>Metsios, G S</creator><creator>Gasparyan, A Y</creator><creator>Carroll, D</creator><creator>Veldhuijzen van Zanten, J J C S</creator><creator>Kitas, G D</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis</title><author>Sandoo, A ; Panoulas, V F ; Toms, T E ; Smith, J P ; Stavropoulos-Kalinoglou, A ; Metsios, G S ; Gasparyan, A Y ; Carroll, D ; Veldhuijzen van Zanten, J J C S ; Kitas, G D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-1a39fbaf727b22e6e5477b8dd70cbda706245d4bc3658305adeaccfbbcf409f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/443/1338/243</topic><topic>692/420</topic><topic>692/699/249/1313/498</topic><topic>692/700/565/251</topic><topic>Adalimumab</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiology. Vascular system</topic><topic>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</topic><topic>Endothelium</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - immunology</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>England</topic><topic>Epidemiology</topic><topic>Etanercept</topic><topic>Health Administration</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Inflammation Mediators - blood</topic><topic>Infliximab</topic><topic>Longitudinal Studies</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microvasculature</topic><topic>Microvessels - drug effects</topic><topic>Microvessels - immunology</topic><topic>Microvessels - physiopathology</topic><topic>Public Health</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>research-letter</topic><topic>Rheumatoid arthritis</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - blood</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sandoo, A</creatorcontrib><creatorcontrib>Panoulas, V F</creatorcontrib><creatorcontrib>Toms, T E</creatorcontrib><creatorcontrib>Smith, J P</creatorcontrib><creatorcontrib>Stavropoulos-Kalinoglou, A</creatorcontrib><creatorcontrib>Metsios, G S</creatorcontrib><creatorcontrib>Gasparyan, A Y</creatorcontrib><creatorcontrib>Carroll, D</creatorcontrib><creatorcontrib>Veldhuijzen van Zanten, J J C S</creatorcontrib><creatorcontrib>Kitas, G D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sandoo, A</au><au>Panoulas, V F</au><au>Toms, T E</au><au>Smith, J P</au><au>Stavropoulos-Kalinoglou, A</au><au>Metsios, G S</au><au>Gasparyan, A Y</au><au>Carroll, D</au><au>Veldhuijzen van Zanten, J J C S</au><au>Kitas, G D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis</atitle><jtitle>Journal of human hypertension</jtitle><stitle>J Hum Hypertens</stitle><addtitle>J Hum Hypertens</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>25</volume><issue>11</issue><spage>699</spage><epage>702</epage><pages>699-702</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21525886</pmid><doi>10.1038/jhh.2011.36</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 2011-11, Vol.25 (11), p.699-702 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_898509294 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; SpringerLink Journals - AutoHoldings |
| subjects | 631/443/1338/243 692/420 692/699/249/1313/498 692/700/565/251 Adalimumab Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arterial hypertension. Arterial hypotension Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - physiopathology Biological and medical sciences Blood and lymphatic vessels Blood pressure Blood Pressure - drug effects Cardiology. Vascular system Clinical manifestations. Epidemiology. Investigative techniques. Etiology Endothelium Endothelium, Vascular - drug effects Endothelium, Vascular - immunology Endothelium, Vascular - physiopathology England Epidemiology Etanercept Health Administration Humans Immunoglobulin G - therapeutic use Inflammation Mediators - blood Infliximab Longitudinal Studies Medical sciences Medicine Medicine & Public Health Microvasculature Microvessels - drug effects Microvessels - immunology Microvessels - physiopathology Public Health Receptors, Tumor Necrosis Factor - therapeutic use research-letter Rheumatoid arthritis Time Factors Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - blood Tumor necrosis factor-α |
| title | Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A16%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-TNF%CE%B1%20therapy%20may%20lead%20to%20blood%20pressure%20reductions%20through%20improved%20endothelium-dependent%20microvascular%20function%20in%20patients%20with%20rheumatoid%20arthritis&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=Sandoo,%20A&rft.date=2011-11-01&rft.volume=25&rft.issue=11&rft.spage=699&rft.epage=702&rft.pages=699-702&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/jhh.2011.36&rft_dat=%3Cproquest_cross%3E898509294%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640623075&rft_id=info:pmid/21525886&rfr_iscdi=true |